1.Renal adverse effects of sunitinib and its clinical significance: a single-center experience in Korea.
Seon Ha BAEK ; Hyunsuk KIM ; Jeonghwan LEE ; Dong Ki KIM ; Kook Hwan OH ; Yon Su KIM ; Jin Suk HAN ; Tae Min KIM ; Se Hoon LEE ; Kwon Wook JOO
The Korean Journal of Internal Medicine 2014;29(1):40-48
BACKGROUND/AIMS: Sunitinib is an oral multitargeted tyrosine kinase inhibitor used mainly for the treatment of metastatic renal cell carcinoma. The renal adverse effects (RAEs) of sunitinib have not been investigated. The aim of this study was to determine the incidence and risk factors of RAEs (proteinuria [PU] and renal insufficiency [RI]) and to investigate the relationship between PU and antitumor efficacy. METHODS: We performed a retrospective review of medical records of patients who had received sunitinib for more than 3 months. RESULTS: One hundred and fifty-five patients (mean age, 58.7 +/- 12.6 years) were enrolled, and the mean baseline creatinine level was 1.24 mg/dL. PU developed in 15 of 111 patients, and preexisting PU was aggravated in six of 111 patients. Only one patient developed typical nephrotic syndrome. Following discontinuation of sunitinib, PU was improved in 12 of 17 patients but persisted in five of 17 patients. RI occurred in 12 of 155 patients, and the maximum creatinine level was 3.31 mg/dL. RI improved in two of 12 patients but persisted in 10 of 12 patients. Risk factors for PU were hypertension, dyslipidemia, and chronic kidney disease. Older age was a risk factor for RI. The median progression-free survival was significantly better for patients who showed PU. CONCLUSIONS: The incidence of RAEs associated with sunitinib was lower than those of previous reports. The severity of RAEs was mild to moderate, and partially reversible after cessation of sunitinib. We suggest that blood pressure, urinalysis, and renal function in patients receiving sunitinib should be monitored closely.
Aged
;
Antineoplastic Agents/*adverse effects
;
Carcinoma, Renal Cell/complications/drug therapy/mortality
;
Female
;
Humans
;
Incidence
;
Indoles/*adverse effects
;
Kidney Neoplasms/complications/drug therapy/mortality
;
Male
;
Middle Aged
;
Proteinuria/*chemically induced/epidemiology
;
Pyrroles/*adverse effects
;
Renal Insufficiency/*chemically induced/epidemiology
;
Republic of Korea/epidemiology
;
Retrospective Studies
;
Risk Factors
;
Treatment Outcome
2.Is there any vindication for low dose nonselective beta-blocker medication in patients with liver cirrhosis?.
Tae Wan KIM ; Hong Joo KIM ; Chang Uk CHON ; Hyun Sun WON ; Jung Ho PARK ; Dong Il PARK ; Yong Kyun CHO ; Chong Il SOHN ; Woo Kyu JEON ; Byung Ik KIM
Clinical and Molecular Hepatology 2012;18(2):203-212
BACKGROUND/AIMS: Nonselective beta-blockers (NSBBs), such as propranolol, reportedly exert a pleiotropic effect in liver cirrhosis. A previous report suggested that survival was higher in patients receiving adjusted doses of NSBBs than in ligation patients. This study investigated whether low-dose NSBB medication has beneficial effects in patients with liver cirrhosis, especially in terms of overall survival. METHODS: We retrospectively studied 273 cirrhotic patients (199 males; age 53.6+/-10.2 years, mean+/-SD) who visited our institution between March 2003 and December 2007; follow-up data were collected until June 2011. Among them, 138 patients were given a low-dose NSBB (BB group: propranolol, 20-60 mg/day), and the remaining 135 patients were not given an NSBB (NBB group). Both groups were stratified randomly according to Child-Turcotte-Pugh (CTP) classification and age. RESULTS: The causes of liver cirrhosis were alcohol (n=109, 39.9%), hepatitis B virus (n=125, 45.8%), hepatitis C virus (n=20, 7.3%), and cryptogenic (n=19, 7.0%). The CTP classes were distributed as follows: A, n=116, 42.5%; B, n=126, 46.2%; and C, n=31, 11.4%. Neither the overall survival (P=0.133) nor the hepatocellular carcinoma (HCC)-free survival (P=0.910) differed significantly between the BB and NBB groups [probability of overall survival at 4 years: 75.1% (95% CI=67.7-82.5%) and 81.2% (95% CI=74.4-88.0%), respectively; P=0.236]. In addition, the delta CTP score did not differ significantly between the two groups. CONCLUSIONS: Use of low-dose NSBB medication in patients with liver cirrhosis is not indicated in terms of overall and HCC-free survival.
Adrenergic beta-Antagonists/*therapeutic use
;
Adult
;
Aged
;
Alcohol Drinking
;
Carcinoma, Hepatocellular/complications/diagnosis
;
Female
;
Follow-Up Studies
;
Humans
;
Kaplan-Meier Estimate
;
Kidney Failure, Chronic/complications/diagnosis
;
Liver Cirrhosis/complications/*drug therapy/mortality
;
Liver Neoplasms/complications/diagnosis
;
Male
;
Middle Aged
;
Predictive Value of Tests
;
Proportional Hazards Models
;
Propranolol/*therapeutic use
;
Retrospective Studies
;
Severity of Illness Index
3.Effect of RAAS Inhibition on the Incidence of Cancer and Cancer Mortality in Patients with Glomerulonephritis.
Ho Jun CHIN ; Se Won OH ; Ho Suk GOO ; Jieun OH ; Jung Woo NOH ; Jong Tae CHO ; Ki Young NA ; Suhnggwon KIM ; Dong Wan CHAE
Journal of Korean Medical Science 2011;26(1):59-66
Angiotensin II type 1 receptor blocker (ARB), which is frequently prescribed in patients with glomerulonephritis (GN), is suggested to increase the risk of cancer. We registered 3,288 patients with renal biopsy and analyzed the relationship between the use of renin-angiotensin-aldosterone system (RAAS) blockade and the incidence of cancer or cancer mortality. After renal biopsy, cancer developed in 33 patients with an incidence rate of 1.0% (95% of CI for incidence: 0.7%-1.3%). There was no difference in the cancer incidence among the groups according to the use of angiotensin-converting enzyme inhibitors (ACEI) or ARB: 1.2% in the None (23/1960), 0.7% in the ARB-only (5/748), 0.4% in the ACEI-only (1/247), and 1.2% in the ACEI-ARB (4/333) (P = 0.487) groups. The cancer mortality was 2.1%, 0.4%, 0.0%, and 0.3% in None, ACEI-only, ARB-only, and ACEI-ARB group, respectively (P < 0.001). The risk of cancer mortality in patients with ARB was only 0.124 (0.034-0.445) compared to that of non-users of ARB by Cox's hazard proportional analysis. In conclusion, prescription of ACEI or ARB in patients with GN does not increase cancer incidence and recipients of ARB show rather lower rates of all-cause mortality and cancer mortality.
Adult
;
Aged
;
Angiotensin II Type 1 Receptor Blockers/*therapeutic use
;
Angiotensin-Converting Enzyme Inhibitors/*therapeutic use
;
Female
;
Follow-Up Studies
;
Glomerulonephritis/complications/diagnosis/*drug therapy
;
Humans
;
Incidence
;
Kidney/pathology
;
Male
;
Middle Aged
;
Neoplasms/complications/*epidemiology/mortality
;
Renin-Angiotensin System/*drug effects
;
Retrospective Studies
;
Risk Factors
4.Effect of RAAS Inhibition on the Incidence of Cancer and Cancer Mortality in Patients with Glomerulonephritis.
Ho Jun CHIN ; Se Won OH ; Ho Suk GOO ; Jieun OH ; Jung Woo NOH ; Jong Tae CHO ; Ki Young NA ; Suhnggwon KIM ; Dong Wan CHAE
Journal of Korean Medical Science 2011;26(1):59-66
Angiotensin II type 1 receptor blocker (ARB), which is frequently prescribed in patients with glomerulonephritis (GN), is suggested to increase the risk of cancer. We registered 3,288 patients with renal biopsy and analyzed the relationship between the use of renin-angiotensin-aldosterone system (RAAS) blockade and the incidence of cancer or cancer mortality. After renal biopsy, cancer developed in 33 patients with an incidence rate of 1.0% (95% of CI for incidence: 0.7%-1.3%). There was no difference in the cancer incidence among the groups according to the use of angiotensin-converting enzyme inhibitors (ACEI) or ARB: 1.2% in the None (23/1960), 0.7% in the ARB-only (5/748), 0.4% in the ACEI-only (1/247), and 1.2% in the ACEI-ARB (4/333) (P = 0.487) groups. The cancer mortality was 2.1%, 0.4%, 0.0%, and 0.3% in None, ACEI-only, ARB-only, and ACEI-ARB group, respectively (P < 0.001). The risk of cancer mortality in patients with ARB was only 0.124 (0.034-0.445) compared to that of non-users of ARB by Cox's hazard proportional analysis. In conclusion, prescription of ACEI or ARB in patients with GN does not increase cancer incidence and recipients of ARB show rather lower rates of all-cause mortality and cancer mortality.
Adult
;
Aged
;
Angiotensin II Type 1 Receptor Blockers/*therapeutic use
;
Angiotensin-Converting Enzyme Inhibitors/*therapeutic use
;
Female
;
Follow-Up Studies
;
Glomerulonephritis/complications/diagnosis/*drug therapy
;
Humans
;
Incidence
;
Kidney/pathology
;
Male
;
Middle Aged
;
Neoplasms/complications/*epidemiology/mortality
;
Renin-Angiotensin System/*drug effects
;
Retrospective Studies
;
Risk Factors